1. Israel Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
EPITOMEE MEDICAL LTD

EPITOMEE MEDICAL LTD

TTASE:EPIT
402.00
ILA
-46.50
(-10.37%)
20.43BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
0.34
- -
0.01
- -
Basic EPS, GAAP
- -
-0.12
-0.11
-0.39
-0.52
-0.19
-0.05
-0.29
- -
Free Cash Flow per Basic Share
- -
-0.1
0.23
-0.21
-0.45
-0.4
-0.43
-0.32
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.06
0.23
0.14
1.81
1.35
1.18
1.15
0.86
0.71
Tangible Book Value per Share
0.06
0.23
0.14
1.81
1.35
1.18
1.15
0.86
0.71
Basic Weighted Avg Shares
29
29
29
29
29
30
30
30
30
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
10
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
4.16
- -
-4,475.12
- -
Depreciation Expense
- -
- -
- -
- -
- -
1
- -
1
- -
Net Income, GAAP
- -
-3
-3
-12
-15
-6
-1
-9
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-56.82
- -
-4,043.19
- -
Working Capital
1
7
20
62
44
33
20
12
8
LT Debt
- -
- -
7
- -
4
4
4
5
5
Total Equity
2
7
4
53
39
35
34
26
21
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-81.12
-58.26
-40.22
-33.19
-15.31
-4.26
-28.75
- -

Capital Structure

USD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
4
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
30
Market Capitalization
76
58
69

Working Capital

USD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
19
14
10
Cash, Cash Equivalents & STI
18
14
9
Accounts Receivable, Net
- -
- -
1
Inventories
- -
- -
1
Total Current Liabilities
2
2
3
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
235.28%
-23.54%
Free Cash Flow
- -
-20.5%
-26.47%
Net Income, GAAP
- -
129.65%
488.25%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

USD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.05
2025
- -
- -
-0.29
2026
- -
- -
- -

Semi-annual Dividends Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Dan Hashimshony
Full Time Employees
44
Sector
Health technology
Industry
Pharmaceuticals: major
Address
17 Hatochon St Caesarea HM Israel 3079892
IPO Date
Dec 14, 2021
Website
epitomeemedical.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Epitomee Medical Ltd (TASE: EPIT), a biomedical company founded in 2005 and headquartered in Caesarea, Israel, develops and commercializes ingestible therapeutic devices worldwide for chronic disease management, with operations focused on weight loss solutions and biologic drug delivery. The company offers polymer-based, self-administered capsules that deploy targeted therapies along the gastrointestinal tract through mechanosensory stimulation in the stomach, duodenum, and small intestine; these include its flagship Epitomee Capsule for weight management, which expands to promote satiety, reduce waist circumference, and improve cardiovascular risk factors in adults with BMI 25-40, alongside a platform for oral delivery of biologics to enhance bioavailability and provide needle-free alternatives to injections. Epitomee operates in the medical devices segment, targeting patients with overweight, obesity, and conditions requiring biologic therapies under physician prescription, with products designed for transient activity followed by natural dissolution and eviction. In September 2024, the company received US FDA clearance for its Epitomee Capsule as a drug-free weight management device, enabling planned US market entry in Q3 2025 through state-by-state distribution partnerships; Nestlé Health Science terminated its prior commercialization agreement for the weight loss capsule at the end of 2023 citing insufficient trial results amid competition from GLP-1 drugs, prompting Epitomee to pursue new distributors. Formerly known as Tulip Medical Ltd, Epitomee continues to advance its dual-segment strategy, reporting initial sales in its weight loss field in 2023 and presenting its oral delivery platform at industry events like PODD 2024.